News Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
2.99 ^USD	+0.34%		-0.99%	-41.94%

15/04	Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	CI
15/04	Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH	25/04	BU
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia	15/04	AQ
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	15/04	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04	CI
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights	15/04	AQ
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting	26/03	AQ
Reviva to Present at the UBS Virtual CNS Day	11/03	AQ
Reviva to Present at the 36th Annual ROTH Conference	07/03	AQ
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	20/02	AQ
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	06/02	AQ
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference	25/01	AQ
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones	04/01	AQ
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum	11/12	AQ
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference	01/12	AQ
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	21/11	MT
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding	20/11	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	17/11	MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	17/11	MT
Sector Update: Health Care	17/11	MT
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall	16/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Summary

Filters